Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: J Immunol. 2018 Oct 29;201(11):3456–3464. doi: 10.4049/jimmunol.1800173

Figure 1. IL-33 reduces tumor growth in Rag1−/− mice.

Figure 1.

(A) WT C57BL/6J mice were given s.c. injections of B16F10 tumor cells. After seven days, 1μg recombinant IL-33 was administered every other day and tumor growth was measured every two days (n=5 mice per group). (B) Rag1−/− mice began recombinant IL-33 treatment as described above 3 days after s.c. injection of B16F10 cells (n=5 mice per group) or (C) EL4 cells (n=4 mice per group). (D) Rag1−/− mice (n=5 mice per group) were s.c. injected with either control B16 cells (B16-Vec) or IL-33-expressing B16 cells (B16-IL33). Data are shown as mean ± SEM. ** P< 0.01, *** P<0.001 as determined using a Student’s t-test.